Figure 6.

Circulating levels of T cells. (A) CD3⁺ T cells, (B) CD56⁺ natural killer (NK) cells, (C) CD4⁺/CD8⁺ T cells, and (D) Treg cells expressed as % of lymphocytes as determined by flow cytometry in patients enrolled in the two arms of the study and treated with rituximab (red triangles) and ofatumumab (blue circles). Data were evaluated before infusion of drugs and at 1–15 months. Gating strategy was described in Supplemental Figure 1. Horizontal lines indicate the medians. Levels of the B cell subpopulations at different time points were analyzed using a nonparametric Kruskal-Wallis test followed by a Dunn’s multiple comparison. *P<0.05.